Why the study?
How do age and high blood pressure alter cardiovascular responsiveness and the efficacy of different antihypertensive drug classes?
How do age and high blood pressure alter cardiovascular responsiveness and the efficacy of different antihypertensive drug classes?
Answers are grounded in this paper and cite their sources.
Age-related changes in adrenergic responsiveness provide a pathophysiological rationale for tailoring antihypertensive therapy, favoring vasodilators in older patients and beta-blockers or ACE inhibitors in younger patients.
With older age and higher blood pressure, defective cardiovascular responses to beta-adrenergic activation allow unopposed alpha 1- and alpha 2-adrenoceptor-mediated vasoconstriction to occur. This helps to explain the transition from early hypertension resulting from an increase in cardiac output and renin secretion to a later form caused by an augmented peripheral vascular resistance. The status of the beta-adrenoceptors aids in determining the response to antihypertensive drugs. Thus, the predominance of beta-adrenergic responses to sympathetic stimulation renders the younger patient more susceptible to antihypertensive therapy with beta-adrenergic blockers or inhibitors of converting enzyme; the latter eliminates the amplifying effect of angiotension II on sympathetic neurotransmission. The blunted cardiovascular counterregulation observed in the older patients favors a response to antihypertensive drugs acting mainly by peripheral vasodilatation, including alpha-adrenergic antagonists and calcium-entry blockers.
No takes yet. Share an insight, caveat, or question.
Bühler et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: